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Abstract
Age-associated telomere shortening is a well documented feature of peripheral blood cells in human population studies,
but it is not known to what extent these data can be transferred to the individual level. Telomere length (TL) in two blood
samples taken at ,10 years interval from 959 individuals was investigated using real-time PCR. TL was also measured in 13
families from a multigenerational cohort. As expected, we found an age-related decline in TL over time (r=–0.164, P,0.001,
n=959). However, approximately one-third of the individuals exhibited a stable or increased TL over a decade. The
individual telomere attrition rate was inversely correlated with initial TL at a highly significant level (r=–0.752, P,0.001),
indicating that the attrition rate was most pronounced in individuals with long telomeres at baseline. In accordance, the
age-associated telomere attrition rate was more prominent in families with members displaying longer telomeres at a
young age (r=–0.691, P,0.001). Abnormal blood TL has been reported at diagnosis of various malignancies, but in the
present study there was no association between individual telomere attrition rate or prediagnostic TL and later tumor
development. The collected data strongly suggest a TL maintenance mechanism acting in vivo, providing protection of
short telomeres as previously demonstrated in vitro. Our findings might challenge the hypothesis that individual TL can
predict possible life span or later tumor development.
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Introduction
Telomeres are protective end structures of the chromosomes.
Telomere length is dictated partly by hereditary [1–6] and partly
by environmental [7,8] and epigenetic factors [9]. The hereditary
impact on TL has been estimated to range between 36–84% [3–
6]. An equally strong telomere length inheritance was reported for
monozygotic (MZ) as for dizygotic (DZ) twin pairs, indicating that
the correlation in TL was mainly due to shared environmental
factors [10]. In contrast, relatively minor environmental effects on
TL during life were suggested in MZ twins where identical
homologue telomeres differed less in TL compared to the two
alleles within one individual [1,2]. Regarding the influence of life
style and environment on telomere maintenance, the published
data are conflicting and no consensus has been reached
concerning the impact of e.g. smoking, blood pressure or serum
lipids on TL (literature overview in [11]).
Patients with smoking associated malignancies, such as human
bladder, head and neck, lung, and renal cell cancers, have been
shown to display shorter blood TL at diagnosis compared to
controls [12,13]. Short blood TL has therefore been suggested as a
predisposition factor for these cancer types. For breast cancer, no
difference in blood TL between patients and controls was found in
one study [14], whereas we recently reported longer telomeres in
peripheral blood cells of breast cancer patients and, furthermore,
that long blood TL indicated a poor survival [15]. Numerous
studies have shown an inverse correlation between blood cell TL
and age [16–18]. Hence, it might be assumed that this
characteristic is also true at the individual level. However, data
are essentially lacking on individual telomere attrition rates and its
relation to the occurrence of malignancy. Martin-Ruiz et al. did
not find an association between telomere length at baseline and
malignancy related mortality in a longitudinal study on individuals
.85 years old [19].
In the present study, we have investigated individual blood cell
telomere shortening in a large cohort of voluntarily donated
samples. Our novel results show that the attrition rate was strongly
correlated to telomere length at baseline, but unrelated to later
tumor development.
Results
In the study cohort of 959 individuals, investigated at two
occasions with 9–11 year intervals, an overall TL shortening
occurred with age as expected (r=20.164, P,0.001) and women
displayed longer telomeres than men (P=0.052, after age-
adjustments). However, about one third (34%) of all individuals
demonstrated a stable TL or even elongated their telomeres over
approximately a decade. There were very little differences between
cases and controls (31.8% and 34.9%, respectively). When the
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relative TL (RTL) value of sample 1, a very strong and inverse
correlation was found (r=20.752, P,0.001; n=959) (Figure 1A).
This finding was also observed when analyzing tumor cases
(r=20.788, P,0.001; n=314) and controls (r=20.730,
P,0.001; n=645) separately (Figure 1B and 1C) To make sure
that the strong correlation was not based on the very highest or
lowest RTL values, the analysis was also made on individuals with
RTL values ,1 and .0.3. This subcohort showed the same
statistical outcome (r=20.623, p,0.001). Moreover, there was no
gender difference (men: r=20.781, p,0.001, women:
r=20.737, p,0.001). Hence, the attrition rate was most
pronounced in individuals displaying the longest telomeres at
baseline.
In a separate cohort of multigenerational families, we selected
13 families encompassing $10 members over at least three
generations, and plotted RTL against age. A parallellity test
revealed statistically significant differences in slope and intercept
values between the 13 families (P,0.001), i.e. the families differed
with regard to telomere shortening over time (Figure 2A). When
the slope value from each family was plotted as a function of the
corresponding intercept, it was found that RTL at young age
(intercept estimated for the age of 14) was highly correlated with
the telomere attrition rate (slope) (r=20.691, P=0.009)
(Figure 2B).
RTL in sample 1 or 2 did not differ between cases and controls
after age-adjustment (Figure 3), indicating that blood TL was not a
potential biomarker for tumor development in prediagnostic
samples. The telomere attrition rate was similar for cases and
controls (P=0.446 after age and sex adjustments) (Figure 4). As
expected, prostate and breast cancer were the most common
tumor types (the distribution of different types is given in Table 1),
and due to the relatively short follow up time after diagnosis (0–
113, mean 34 months) events of deaths were few. When all tumor
cases were analyzed as one group, shorter than median RTL (for
all tumor cases) in sample 1 ($9 years before diagnosis) indicated a
poor prognosis (not shown in figure). This is illustrated in the
largest tumor group, prostate cancer (n=81), where all deaths
were found in the short RTL group in sample 1 (P=0.004; cut
off=median RTL value for prostate cancer cases) (Figure 5).
When the same analysis was performed for RTL in sample 2
(collected 0–11 years before diagnosis) no significant prognostic
difference was found between prostate cancer patients with long
versus short telomeres (P=0.174). Moreover, no association
between telomere attrition rate and prognosis was found neither
in the entire tumor group nor in the prostate cancer group
(P=0.266 and P=0.889, respectively).
Discussion
Age-associated telomere shortening is a generally accepted
finding based on large cross-sectional studies. It has been assumed
that this characteristic telomere attrition is true at the individual
level as well. It has also been speculated that the telomere attrition
rate in blood cells of tumor patients is higher compared to
Figure 1. RTL and yearly telomere loss over a 9–11 year period. (A) There was a highly significant and inverse correlation between RTL in




An age-dependent telomere shortening has been fre-
quently observed in cross-sectional studies on human
blood cells. Telomerase is an enzyme capable of length-
ening telomeres, and it is activated in most tumor cells in
order for them to become immortalized. This is one of the
first longitudinal studies on telomere length, investigated
in human blood samples taken at two occasions with
approximately 10 years between them. An interesting
finding was that the individual telomere length in the first
blood sample was highly correlated with telomere attrition
rate. Thus, individuals displaying the longest telomeres at
baseline showed the most rapid telomere shortening over
time and vice versa. This was also observed at the family
level when exploring a multigenerational cohort. These
results are in concordance with the fact that telomerase
seems to preferentially act on the shortest telomeres in
cultivated cells and provide fundamental knowledge for
general telomere and cell biology. Because one part of the
cohort developed tumors after the second blood draw, we
had the opportunity to examine whether telomere
attrition rate differed in tumor patients compared with
controls, but no such indication was observed. However,
for prostate cancer, short telomere length $9 years before
diagnosis seemed to predict death.
Individual Telomere Attrition Rate
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expected decline in telomere length by time, but we also observed
large individual differences. Actually, in about one third of all
individuals an elongation of the telomeres occurred over a decade.
Most interestingly, individuals displaying the longest telomeres at
the first blood draw demonstrated the most pronounced telomere
shortening over time, and vice versa. The average coefficient of
variation for the method was ,6% and some of the variation in
TL might be related to the technique itself. However, to make sure
that the strong correlation was not based on the very highest or
lowest RTL values, the correlation analysis was also made on
individuals with RTL values ,1 and .0.3. The result of the
restricted correlation analysis was very similar to the result of the
larger analysis, showing a strong correlation between telomere
length at baseline and attrition rate.
A large variation in telomere attrition at the individual level has
been observed in previous longitudinal studies on telomere length
[19–21]. In a very recent study by Aviv et al. [21], TL was
measured in leukocytes collected on two occasions from 450 whites
and 185 African Americans, participating in the Bogalusa Heart
Study. The median time period between the first and second blood
sampling was shorter compared to our study (,6 years vs. ,10
years), and the participants were fewer and younger (age range:
20.0–40.0 years at baseline). Nevertheless, they found that the age-
dependent TL attrition rate was proportional to TL at baseline,
which is in accordance to our present study. The majority of
Figure 2. Correlation between RTL and attrition rate in 13 separate families. Each family contained 10 or more (maximum 28) related
individuals (i.e., no in-laws). (A) Illustration of telomere shortening with age in 13 individual families. The separate regression lines were obtained by
plotting RTL vs. age for each individual in a family. (B) Telomere attrition rate (i.e. slope) in the 13 families in relation to the estimated RTL at age 14i n
each family, showing a strong negative correlation.
doi:10.1371/journal.pgen.1000375.g002
Figure 3. Blood RTL could not predict future tumor develop-
ment. There was no difference between future tumor patients and
controls regarding RTL measured $9 years before diagnosis (RTL
sample 1) or measured 0–11 years before diagnosis (RTL sample 2).
doi:10.1371/journal.pgen.1000375.g003
Figure 4. Individual telomere attrition rate was not a marker
for future tumor development. Yearly telomere loss at the
individual level did not differ between future tumor patients and
controls.
doi:10.1371/journal.pgen.1000375.g004
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African Americans and 88.0% of whites), whereas the rest
displayed a stable or increased TL. Similar to our observation,
they also found that the rate of TL shortening varied considerably
among individuals.
One explanation to the variations in attrition rate could be
differences in epigenetic regulation, with secondary effects on
telomere maintenance. Another reason might be that telomerase
act preferentially on short telomeres, which has been shown in
mice models and cell culture systems [22–26]. This would be in
line with our observation of a very strong inverse correlation
between individual TL at baseline and telomere attrition over
time. Interestingly, we found a similar result in our separate family
cohort. Hence, comparable data were obtained when analyzing
telomere attrition rate at both the individual and at the family
level. In the present study, individuals with the shortest TL
actually elongated their telomeres over a decade, indicating that
the TL maintenance machinery is focused on protecting the
shortest telomeres. Nevertheless, other factors are likely to
influence the TL attrition rate as well. In our study, the correlation
value between blood RTL at baseline (sample 1) and attrition rate
was r=20.752 when analyzing the entire cohort. The corre-
sponding r-squared value is hence 0.566, or ,57%. This means
that the telomere length at time point 1 could explain 57% of the
variation in attrition rate. Thus, 43% of the variation might well
be explained by other factors, such as life style, oxidative stress,
inflammation etc. In the study by Aviv et al. [21], oxidative stress
was proposed as a potential candidate for causing proportional
telomere shortening. We agree that oxidative stress is likely to be
important for telomere attrition, but the theory does not explain
why a subset of the cohort demonstrated TL elongation. We
suggest that a cellular TL regulating mechanism, rather than
environmental/life style factors, is the major factor determining
the rate of telomere attrition over time.
The working hypothesis that blood cell TL can indicate a later
development of a malignant tumor was not supported in the
present study. This hypothesis emanates from data showing altered
TL in cases with a variety of malignancies. In urinary bladder,
head and neck, lung, and renal cell cancers, shortened blood
telomeres have been described at diagnosis, whereas data on
breast cancer indicate unchanged or longer telomeres compared to
controls [12–15]. Since no difference in TL existed between cases
and controls, neither $9 (sample 1) nor 0–11 (sample 2) years
before the appearance of a malignancy, we conclude that blood
TL is not a prediagnostic biomarker for malignancy per se.
However, our cases suffered from a variety of tumors and we
cannot exclude that blood TL might be a biomarker for specific
tumor types. A support for this is a recent study indicating that
short blood telomeres were associated with a decreased risk for
melanoma but also an increased risk for basal cell carcinoma,
whereas there was no trend for squamous cell carcinoma [27].
In the largest tumor group in our material, prostate cancer, the
blood TL $9 years before diagnosis seemed to indicate a poor
prognosis. All prostate cancer cases with long blood telomeres
(.median) were alive five years after diagnosis compared to
,60% in the group with short telomeres. However, in the sample
taken 0–11 years before prostate cancer diagnosis, TL did not give
prognostic information. Thus, since the same prostate cancer
patients were studied at different time points ahead of the cancer
diagnosis, a shift had occurred indicating differences in the rate of
telomere loss. This shift is interesting, since for breast cancer,
blood TL at diagnosis seems to be a strong prognostic biomarker,
with longer telomeres associated with a worse prognosis [15]. We
have obtained similar data for renal cell carcinoma [Svenson et al.,
unpublished data] indicating that this feature is not unique for
breast cancer. Unfortunately, in the present material the other
cancer groups were too small to allow this type of statistical
calculations. The biological background for these findings is
unclear but it is tempting to speculate that factors responding to
the presence of a tumor also have an impact on telomere
maintenance, especially in immune reactive cells and their
precursors. Due to few events in the cancer group a more
definitive analysis of prediagnostic TL in relation to prognosis
must await longer follow up times.
In conclusion, and similar to what have been observed in
cultured cells in vitro, human blood cells in vivo seem to have a
telomere maintenance system that gives priority to short telomeres.
Based on human cross-sectional studies of age-associated telomere
attrition, it has been speculated that TL at a certain age can
predict a theoretical future life span. Our findings indicate that TL
regulation through life might be more complex than previously
known, complicating such life span predictions. We suggest that, at
Figure 5. Blood RTL and prognosis in prediagnostic samples
from prostate cancer patients. Shorter than median RTL $9 years
before diagnosis was associated with decreased survival.
doi:10.1371/journal.pgen.1000375.g005
Table 1. Distribution of different tumor types.
Tumor Type Number % of Total
Prostate cancer 81 25.8%
Breast cancer 56 17.8%
Colorectal cancer 40 12.7%
Hematopoietic malignancies 33 10.5%
Malignant melanoma 15 4.8%
Endometrial cancer 12 3.8%
Lung cancer 10 3.2%
Liver/Hepatic duct cancer 9 2.9%
Renal cancer 8 2.5%
Brain tumors 7 2.2%
Ovarian cancer 5 1.6%
Others 38 12.1%
doi:10.1371/journal.pgen.1000375.t001
Individual Telomere Attrition Rate
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that senses the telomere length similar to the counting mechanism
demonstrated in cells from different species [28–31]. However, it
might well be possible to avoid excessive telomere loss by living a
healthy life as recently indicated [32]. Our data has important
implications for our understanding of human telomere biology and
for future analyses of telomere maintenance mechanisms in vivo.
Materials and Methods
Study Cohorts
The North Sweden Health and Disease Study (NSHDS) include
the Va ¨sterbotten Intervention Project (VIP), launched in 1985 in
the County of Va ¨sterbotten, the cardiovascular research program
Monitoring of Trends and Determinants in Cardiovascular
Diseases (MONICA) and the local Mammography Screening
Project (MSP) [33]. At present the population based NSHDS
collection contains samples from around 85000 individuals, nearly
all Caucasians. Blood was drawn with anticoagulants, separated
into plasma, erythrocyte and buffy coat fractions and stored at
280uC in small aliquots. In the NSHDS collection we identified
.7000 individuals who had donated blood samples at a ,10 year
interval (9–11 years) and of these 343 persons had obtained a
cancer diagnosis after the second blood sample (time from sample
2 to diagnosis: 0–11 years, mean 2.7) (Figure 6). From the same
cohort, 686 age and sex matched controls were also selected. The
age span was 30–61 years for sample 1 and 40–70 years for sample
2. Cancer cases were identified through record linkages with the
regional Cancer Register. Due to insufficient amounts of buffy
coat cells for DNA extraction or unsuccessful RT-PCR, 314 cases
and 645 controls (totally 1918 samples) were included in the
statistical analyses (cases: 176 men and 138 women; controls: 361
men and 284 women).
To permit analysis of a possible family linked pattern regarding
TL attrition, a multifamily cohort was also utilized, initially aimed
at studying genetic and environmental factors influencing heredity
of personality traits, upbringing, general health and longevity (a
study designed and conducted in the late 90’s by the author RA).
In total, whole blood was available from 962 individuals in 68
families (445 men and 517 women) with an age span of 0–102
years. Thirteen of these families could be selected for the purpose
of this study (se statistics below).
Ethics Statement
The study was approved by the Umea ˚ University Ethical
Committee.
Telomere Length Determination
DNA was extracted from buffy coats and whole blood using
conventional methods. Relative telomere length was measured
using quantitative real-time PCR as described previously [34,35].
In short, telomeres and a single copy gene (b2-globin) were
amplified in all samples including an internal reference control cell
line (CCRF-CEM) to which all samples were compared. The
DDCt method was used for calculation of RTL values and a
standard curve was created in each PCR run to monitor the PCR
efficiency. The mean inter-assay coefficient of variation for this
method ranges between 4–8% in our laboratory.
Statistics
Normality was shown regarding RTL distributions. Pearson
partial correlation was performed to calculate age-adjusted
correlations between continuous variables. ANCOVA was used
for age and/or sex adjusted comparisons between groups.
Cumulative survival for cancer patients with long vs. short
telomeres was investigated using Kaplan-Meier with the log-rank
test. Survival was defined as the number of months between
diagnosis date to death or to last follow-up (Feb 2008).
To investigate whether the rate of telomere loss with age was
linked to TL at a young age, 13 separate families in the
multifamily cohort were studied. In each family, samples from
10 or more (maximum 28) related individuals, i.e. no in-laws, were
available in at least three generations. The age of the individuals in
the youngest generation varied between 14 and 32 years and in the
oldest generation between 70 and 101 years. The number of men
and women was similar within all families except for one which
contained more women. The RTL values were plotted against age
and linear regression was used to generate intercept (‘‘starting
RTL’’) and slope (telomere loss) values for each family. The
calculated intercepts corresponded to the estimated RTL value at
the age of 14. The slope was then plotted as a function of the
intercept and the correlation was examined using Pearson’s
Correlation Coefficient. MLwiN [36], a software for multilevel
analysis, was used to test for parallellity between the 13 regression
lines. All other statistics were analyzed in SPSS 15.0. A P-value
#0.05 was considered to be significant.
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